Session attendees will hear about recent successes from the Government Affairs Committee and learn how to become effective rheumatology advocates.
Practice & Society Donations Advance Advocacy Efforts for Rheumatologists & Patients
A new RheumPAC fund, which supports awareness and operations of the ACR’s political action committee, has exceeded an initial goal of $20,000 by two times in its first year.
Innovative Education Formats & More: What’s New at the 2019 ACR/ARP Annual Meeting
With innovative session formats and unique spaces that encourage learning and networking, the 2019 ACR/ARP Annual Meeting will offer exciting new opportunities for rheumatology professionals. Here’s a sneak peek…
Sit Back & Enjoy Learning at the 2019 ACR/ARP Annual Meeting
With innovative session formats and unique spaces that encourage networking, the 2019 ACR/ARP Annual Meeting will offer new and exciting opportunities for rheumatology professionals. Here’s a sneak peek…
Gut Instinct: Ankylosing Spondylitis & the Microbiome
CHICAGO—At the 2019 ACR State-of-the-Art Clinical Symposium, an annual gathering featuring talks by key opinion leaders on the most salient topics for practicing rheumatologists and healthcare providers, Jose U. Scher, MD, director of the Microbiome Center for Rheumatology and Autoimmunity at NYU Langone Medical Center, New York City, was the featured speaker. In his remarks,…
Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease
NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in…
Imagining a Life Free from the Pain of Ankylosing Spondylitis
Dan Reynolds, the lead singer of the Grammy award-winning band Imagine Dragons, has partnered with Novartis to increase awareness of ankylosing spondylitis.
Abx464 Enters Phase 2 Clinical Trials for RA in Europe
In Europe, researchers are evaluating the safety, tolerability and efficacy of ABX464 in rheumatoid arthritis patients…
The Bath Ankylosing Spondylitis Functional Index’s History & Patient View
Sir William Osler, widely regarded as one of the greatest physicians of the 20th century, once said, “He who studies medicine without books sails an uncharted sea, but he who studies medicine without patients does not go to sea at all.”1 This sentiment is particularly true in the field of rheumatology, in which understanding the…
Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective
It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondyloarthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…
- « Previous Page
- 1
- …
- 239
- 240
- 241
- 242
- 243
- …
- 815
- Next Page »